Stockreport

Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]

Protara Therapeutics, Inc.  (TARA) 
PDF TARA-002's 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. [Read more]